Elizabeth Alexander
Overview
Explore the profile of Elizabeth Alexander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
988
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nader A, Alexander E, Brintziki D, Haggag A, Harrison S, Hawes I, et al.
Clin Pharmacokinet
. 2023 Nov;
63(1):57-68.
PMID: 37955825
Background And Objective: Sotrovimab 500 mg administered by a single intravenous (IV) infusion has been granted special approval for emergency use in Japan for treatment of SARS-CoV-2 infection in adults...
2.
Satram S, Ghafoori P, Reyes C, Keeley T, Birch H, Brintziki D, et al.
J Patient Rep Outcomes
. 2023 Sep;
7(1):92.
PMID: 37702920
Background: The COMET-ICE trial demonstrated that sotrovimab clinically and statistically significantly reduces the risk of all-cause > 24-h hospitalization or death due to any cause among patients with COVID-19 at...
3.
Maher M, Soriaga L, Gupta A, Chen Y, di Iulio J, Ledoux S, et al.
Cell Rep Med
. 2022 Aug;
3(8):100721.
PMID: 35977462
Understanding who is at risk of progression to severe coronavirus disease 2019 (COVID-19) is key to clinical decision making and effective treatment. We study correlates of disease severity in the...
4.
Costa A, Frankova V, Robert G, Macek M, Patch C, Alexander E, et al.
J Community Genet
. 2022 Jun;
13(3):365-369.
PMID: 35773560
No abstract available.
5.
Costa A, Frankova V, Robert G, Macek M, Patch C, Alexander E, et al.
J Community Genet
. 2022 May;
13(3):313-327.
PMID: 35523996
The communication of genomic results to patients and families with rare diseases raise distinctive challenges. However, there is little evidence about optimal methods to communicate results to this group of...
6.
Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci D, et al.
JAMA
. 2022 Mar;
327(13):1236-1246.
PMID: 35285853
Importance: Older patients and those with comorbidities who are infected with SARS-CoV-2 may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody for the treatment of...
7.
Paukner S, Goldberg L, Alexander E, Das A, Heinrich S, Patel P, et al.
J Glob Antimicrob Resist
. 2021 Nov;
29:434-443.
PMID: 34788694
Objectives: Lefamulin, a pleuromutilin antibiotic approved for community-acquired bacterial pneumonia (CABP), was evaluated for microbiological efficacy in a prespecified pooled analysis of LEAP 1 and 2 phase 3 clinical trial...
8.
Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci D, et al.
N Engl J Med
. 2021 Oct;
385(21):1941-1950.
PMID: 34706189
Background: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent...
9.
File Jr T, Alexander E, Goldberg L, Das A, Sandrock C, Paukner S, et al.
BMC Pulm Med
. 2021 May;
21(1):154.
PMID: 33964925
Background: Lefamulin, a first-in-class pleuromutilin antibiotic approved for intravenous and oral use in adults with community-acquired bacterial pneumonia (CABP), was noninferior to moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP)...
10.
LoVecchio F, Schranz J, Alexander E, Mariano D, Meads A, Sandrock C, et al.
J Emerg Med
. 2021 Mar;
60(6):781-792.
PMID: 33731270
Background: Safe and effective oral antibiotics are needed for outpatient management of moderate to severe community-acquired bacterial pneumonia (CABP). Objective: We describe a post-hoc analysis of adults with CABP managed...